Xemilofiban

Drug Profile

Xemilofiban

Alternative Names: SC 54684; SC 54684A; Xemlofiban

Latest Information Update: 09 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Searle.
  • Class Benzamidines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 09 Dec 2015 Xemilofiban is still available for out-licensing or co-development opportunities (http://www.virtualdrugdevelopment.com)
  • 01 Oct 2003 Xemilofiban is available for licensing (www.vddipharmaceuticals.com)
  • 12 Feb 2003 Clinical trials in Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top